Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction

References

• Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci. 2018;132(12):1243–1252. doi:10.1042/CS20180306
   PubMed Web of Science ®Google Scholar
• Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515–581. doi:10.1152/physrev.00024.2005
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1–27. doi:10.3390/ijms19071890
   Web of Science ®Google Scholar
• Gasparyan AY. Cardiovascular risk and inflammation in rheumatic diseases. Rheumatol Int. 2017;37(1):1–2. doi:10.1007/s00296-016-3619-8
   PubMed Web of Science ®Google Scholar
• Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf. 2018;41(5):473–488. doi:10.1007/s40264-017-0628-9
   PubMed Web of Science ®Google Scholar
• Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016;8(3):86–101. doi:10.1177/1759720X16643340
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28. doi:10.1136/annrheumdis-2016-209775
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou AD, Konstantonis G, Fragiadaki K, Kitas GD, Sfikakis PP. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology. 2017;56:934–939. doi:10.1093/rheumatology/kew506
   PubMed Web of Science ®Google Scholar
• Jamthikar AD, Gupta D, Puvvula A, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis using carotid ultrasound B-mode imaging. Rheumatol Int. 2020;40(12):1921–1939. doi:10.1007/s00296-020-04691-5
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37(22):1723–1732. doi:10.1093/eurheartj/ehv759
   PubMed Web of Science ®Google Scholar
• Drakopoulou M, Soulaidopoulos S, Oikonomou G, Tousoulis D, Toutouzas K. Cardiovascular effects of biologic disease-modifying anti-rheumatic drugs (DMARDs). Curr Vasc Pharmacol. 2020;18(5):488–506. doi:10.2174/1570161118666200214115532
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, Libby P. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Eur Heart J. 2020;41(23):2153–2163. doi:10.1093/eurheartj/ehz542
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734–736. doi:10.1016/j.atherosclerosis.2011.09.015
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409–1417. doi:10.1007/s00296-011-1999-3
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704. doi:10.1038/nrrheum.2015.112
   PubMed Web of Science ®Google Scholar
• Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8–14. doi:10.1136/ard.2010.142133
   PubMed Web of Science ®Google Scholar
• Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2020;3(1):e58–e70. doi:10.1016/S2665-9913(20)30221-6
   PubMedGoogle Scholar
• Kisiel B, Kruszewski R, Juszkiewicz A, et al. Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis. J Immunol Res. 2015;2015:1–8. doi:10.1155/2015/759610
   Web of Science ®Google Scholar
• Steyers CM, Miller FJ. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. 2014;15(7):11324–11349. doi:10.3390/ijms150711324
   PubMed Web of Science ®Google Scholar
• Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev. 2010;9(12):830–834. doi:10.1016/j.autrev.2010.07.016
   PubMed Web of Science ®Google Scholar
• Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-α and complement component 3 on coagulation. Sci Rep. 2018;8(1):1–9. doi:10.1038/s41598-018-20220-8
   PubMedGoogle Scholar
• Bamias G, Stamatelopoulos K, Zampeli E, et al. Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol. 2013;147(2):144–150. doi:10.1016/j.clim.2013.03.002
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Hodson J, Sandoo A, Smith J, Kitas GD. Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. Arthritis Res Ther. 2017;19(1):32. doi:10.1186/s13075-017-1232-1
   PubMedGoogle Scholar
• Dimitroulas T, Sandoo A, Douglas K, Kitas G. Symmetric and asymmetric dimethylarginines as biochemical markers of endothelial dysfunction and atherosclerosis in Rheumatoid Arthritis. Mediterr J Rheumatol. 2015;26(2):62–75.
   Google Scholar
• Dimitroulas T, Douglas KM, Panoulas VF, et al. Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors. Clin Rheumatol. 2013;32(9):1357–1364. doi:10.1007/s10067-013-2283-6
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int. 2011;31(2):153–164. doi:10.1007/s00296-010-1446-x
   PubMed Web of Science ®Google Scholar
• Al-Rawi ZS, Gorial FI, Al-Bayati AA. Red cell distribution width in rheumatoid arthritis. Mediterr J Rheumatol. 2018;29(1):38–42. doi:10.31138/mjr.29.1.38
   PubMedGoogle Scholar
• Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. Semin Thromb Hemost. 2010;36(4):452–457. doi:10.1055/s-0030-1254054
   PubMed Web of Science ®Google Scholar
• Lopatko I, Ståhl A, Mossberg M, et al. Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. EBioMedicine. 2019;47:319–328.
   PubMed Web of Science ®Google Scholar
• van Diepen JA, Berbée JFP, Havekes LM, Rensen PCN. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 2013;228(2):306–315. doi:10.1016/j.atherosclerosis.2013.02.028
   PubMed Web of Science ®Google Scholar
• E. Toms T, P. Symmons D, D. Kitas G. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8(3):301–326. doi:10.2174/157016110791112269
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482–487. doi:10.1136/ard.2010.135871
   PubMed Web of Science ®Google Scholar
• Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment–a prospective, controlled study. Arthritis Res Ther. 2006;8(3):R82. doi:10.1186/ar1952
   PubMed Web of Science ®Google Scholar
• Sattar N, Kitas GD. Rheumatoid arthritis: testing the inflammation-insulin resistance link in clinical trials. Nat Rev Rheumatol. 2013;9(12):702–703. doi:10.1038/nrrheum.2013.178
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Body-size phenotypes and cardiometabolic risk in Rheumatoid Arthritis (Short Title: subgroups of obesity in RA). Mediterr J Rheumatol. 2016;27(2):48–54. doi:10.31138/mjr.27.2.48
   Google Scholar
• Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arter Thromb Vasc Biol. 2009;29(10):1702–1708. doi:10.1161/ATVBAHA.109.190108
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Halilova KI, Brown EE, Morgan SL, et al. Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol. 2012;2012:1–7. doi:10.1155/2012/978396
   Google Scholar
• Ridker PM. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. J Intern Med. 2019;285(5):503–509. doi:10.1111/joim.12862
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi:10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology. 2018;57(1):i4–i11. doi:10.1093/rheumatology/kex453
   PubMedGoogle Scholar
• Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126:1260–1280. doi:10.1161/CIRCRESAHA.120.315937
   PubMed Web of Science ®Google Scholar
• Seropian IM, Toldo S, Van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following St-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63(16):1593–1603. doi:10.1016/j.jacc.2014.01.014
   PubMed Web of Science ®Google Scholar
• Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (vcu-art2) pilot study]. Am J Cardiol. 2013;111(10):1394–1400. doi:10.1016/j.amjcard.2013.01.287
   PubMed Web of Science ®Google Scholar
• Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115(3):288–292. doi:10.1016/j.amjcard.2014.11.003
   PubMed Web of Science ®Google Scholar
• Morton AC, Rothman AMK, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–384. doi:10.1093/eurheartj/ehu272
   PubMed Web of Science ®Google Scholar
• Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure - The whys and wherefores. Heart Fail Rev. 2006;11(1):83–92. doi:10.1007/s10741-006-9196-2
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128(17):1910–1923. doi:10.1161/CIRCULATIONAHA.113.003199
   PubMed Web of Science ®Google Scholar
• van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438. doi:10.1371/journal.pone.0033438
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Abouzaki NA, Erdle CO, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. 2016;67(6):544–551. doi:10.1097/FJC.0000000000000378
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Canada J, Carbone S, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017;10(11).
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Trankle CR, Canada JM, et al. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(8):e005036. doi:10.1161/CIRCHEARTFAILURE.118.005036
   PubMed Web of Science ®Google Scholar
• Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906–1912. doi:10.1001/jama.2016.15826
   PubMed Web of Science ®Google Scholar
• Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33(12):2440–2446.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921–923.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, Notarsanto I, de Pinto GD, et al. Anti-tumor necrosis factor-alpha therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients. Intern Emerg Med. 2010;5(6):495–500. doi:10.1007/s11739-010-0458-6
   PubMed Web of Science ®Google Scholar
• Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 2012;25(6):644–650. doi:10.1038/ajh.2012.12
   PubMed Web of Science ®Google Scholar
• Angel K, Provan SA, Hammer HB, Mowinckel P, Kvien TK, Atar D. Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundam Clin Pharmacol. 2011;25(4):511–517. doi:10.1111/j.1472-8206.2010.00872.x
   PubMed Web of Science ®Google Scholar
• van Sijl AM, Peters MJ, Knol DL, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2011;41(3):393–400. doi:10.1016/j.semarthrit.2011.04.003
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment. Curr Vasc Pharmacol. 2020;18(5):431–446.
   PubMed Web of Science ®Google Scholar
• Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015;67(1):117–127. doi:10.1002/art.38894
   PubMed Web of Science ®Google Scholar
• Makrilakis K, Fragiadaki K, Sfikakis PP, Kitas GD. Chemerin and cardiovascular risk in rheumatoid arthritis after interleukin 6 receptor blockade. J Rheumatol. 2015;42(2):349. doi:10.3899/jrheum.141115
   PubMed Web of Science ®Google Scholar
• McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694–702. doi:10.1136/annrheumdis-2013-204345
   PubMed Web of Science ®Google Scholar
• Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009;28(6):705–710. doi:10.1007/s10067-009-1095-1
   PubMed Web of Science ®Google Scholar
• Virone A, Bastard JP, Fellahi S, et al. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019;5(2):e000897. doi:10.1136/rmdopen-2019-000897
   PubMed Web of Science ®Google Scholar
• Leporini C, Russo E, D’Angelo S, et al. Insulin-sensiting effects of tumor necrosis factor alpha inhibitors in rheumatoid arthritis: a systematic review and meta-analysis. Rev Recent Clin Trials. 2018;13(3):184–191. doi:10.2174/1574887113666180314100340
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, Kitas GD. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R160. doi:10.1186/ar3900
   PubMed Web of Science ®Google Scholar
• Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141. doi:10.1186/ar3874
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: an observational study. Med. 2019;98(7):e14587. doi:10.1097/MD.0000000000014587
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Gravos A, Vlachopoulos C, et al. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34(2):359–364. doi:10.1007/s10067-014-2718-8
   PubMed Web of Science ®Google Scholar
• Sandoo A, Veldhuijzen van Zanten JJCS, Metsios GS, et al. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatol. 2011;50(11):2125–2139. doi:10.1093/rheumatology/ker275
   PubMed Web of Science ®Google Scholar
• Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor-alpha antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum. 2012;42(1):1–8. doi:10.1016/j.semarthrit.2012.02.002
   PubMed Web of Science ®Google Scholar
• Zhu TY, Griffith JF, Qin L. Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT. J Bone Miner Res. 2014;29(9):2118–2129. doi:10.1002/jbmr.2221
   PubMed Web of Science ®Google Scholar
• Tam LS, Kitas GD, Gonzalez-Gay MA. Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatol. 2014;53(6):1108–1119. doi:10.1093/rheumatology/ket454
   PubMed Web of Science ®Google Scholar
• Plein S, Erhayiem B, Fent G, et al. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis. Ann Rheum Dis. 2020;79(11):1414–1422. doi:10.1136/annrheumdis-2020-217653
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti‐TNFα treatment in rheumatoid arthritis patients. Scand J Rheumatol. 2009;38(1):6–10. doi:10.1080/03009740802363768
   PubMed Web of Science ®Google Scholar
• Tam LS, Shang Q, Li EK, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis – a randomized trial. J Rheumatol. 2012;39(12):2267–2275. doi:10.3899/jrheum.120541
   PubMed Web of Science ®Google Scholar
• Peters MJ, van Sijl AM, Voskuyl AE, Sattar N, Smulders YM, Nurmohamed MT. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des. 2012;18(11):1502–1511. doi:10.2174/138161212799504786
   PubMed Web of Science ®Google Scholar
• Ursini F, Leporini C, Bene F, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017;7(1):5346. doi:10.1038/s41598-017-05759-2
   PubMedGoogle Scholar
• Tam LS, Li EK, Shang Q, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis. 2011;70(4):705–706. doi:10.1136/ard.2010.131359
   PubMed Web of Science ®Google Scholar
• Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169–2171. doi:10.3899/jrheum.110340
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008;59(12):1821–1824. doi:10.1002/art.24308
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics. 2013;7:69–75. doi:10.2147/BTT.S39182
   PubMedGoogle Scholar
• Sandoo A, Kitas GD. The impact of abatacept treatment on the vasculature in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(4):589.
   PubMed Web of Science ®Google Scholar
• Benucci M, Bandinelli F, Damiani A, et al. Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis. J Inflamm Res. 2018;11:247–252. doi:10.2147/JIR.S156822
   PubMed Web of Science ®Google Scholar
• Low AS, Symmons DP, Lunt M, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(4):654–660. doi:10.1136/annrheumdis-2016-209784
   PubMed Web of Science ®Google Scholar
• Low AS, Lunt M, Mercer LK, et al. Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68(6):1337–1345. doi:10.1002/art.39582
   PubMed Web of Science ®Google Scholar
• Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30. doi:10.1186/ar2383
   PubMed Web of Science ®Google Scholar
• Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018;20(1):171. doi:10.1186/s13075-018-1669-x
   PubMed Web of Science ®Google Scholar
• Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63(4):522–529. doi:10.1002/acr.20371
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. doi:10.1136/annrheumdis-2014-206624
   PubMed Web of Science ®Google Scholar
• Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399–405. doi:10.1016/j.semarthrit.2018.03.012
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res. 2019;71(8):1004–1018. doi:10.1002/acr.23737
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–1224.
   PubMed Web of Science ®Google Scholar
• Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31–40. doi:10.1002/art.41095
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2020;72(4):561–576. doi:10.1002/acr.23875
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761–1766. doi:10.3899/jrheum.150051
   PubMed Web of Science ®Google Scholar
• van Sijl AM, van der Weele W, Nurmohamed MT. Myocardial infarction after rituximab treatment for rheumatoid arthritis: is there a link? Curr Pharm Des. 2014;20(4):496–499.
   PubMed Web of Science ®Google Scholar
• Lee L, Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol. 2012;2012:984986. doi:10.1155/2012/984986
   PubMedGoogle Scholar
• Kang EH, Jin Y, Brill G, et al. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc. 2018;7(3).
   Web of Science ®Google Scholar
• Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018;45(9):1240–1248. doi:10.3899/jrheum.170926
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813–1818. doi:10.1136/annrheumdis-2015-207870
   PubMed Web of Science ®Google Scholar
• van Eijk IC, de Vries MK, Levels JH, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 2009;60(5):1324–1330. doi:10.1002/art.24492
   PubMedGoogle Scholar
• Mathieu S, Dubost JJ, Tournadre A, Malochet-Guinamand S, Ristori JM, Soubrier M. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Jt Bone Spine. 2010;77(1):50–52. doi:10.1016/j.jbspin.2009.05.012
   PubMed Web of Science ®Google Scholar
• Min HK, Lee J, Ju JH, Park SH, Kwok SK. Impact of TNF-alpha inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the Catholic Axial Spondyloarthritis COhort (CASCO). Clin Rheumatol. 2020;39(2):471–477. doi:10.1007/s10067-019-04767-z
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga M, Kneepkens EL, van Dongen C, Nurmohamed MT. The effects of 5-year etanercept therapy on cardiovascular risk factors in patients with psoriatic arthritis. J Rheumatol. 2017;44(9):1362–1368. doi:10.3899/jrheum.161418
   PubMed Web of Science ®Google Scholar
• Arida A, Protogerou AD, Konstantonis G, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol. 2015;42(11):2098–2105. doi:10.3899/jrheum.150316
   PubMedGoogle Scholar
• Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatol. 2012;51(5):910–914. doi:10.1093/rheumatology/ker434
   PubMed Web of Science ®Google Scholar
• Tam LS, Shang Q, Kun EW, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatol. 2014;53(6):1065–1074. doi:10.1093/rheumatology/ket469
   PubMed Web of Science ®Google Scholar
• Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatol. 2013;52(1):204–209. doi:10.1093/rheumatology/kes272
   PubMed Web of Science ®Google Scholar
• Syngle A, Vohra K, Sharma A, Kaur L. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. Clin Rheumatol. 2010;29(7):763–770. doi:10.1007/s10067-010-1402-x
   PubMed Web of Science ®Google Scholar
• Genre F, Lopez-Mejias R, Miranda-Filloy JA, et al. Anti-TNF-alpha therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatol Int. 2015;35(12):2069–2078. doi:10.1007/s00296-015-3314-1
   PubMed Web of Science ®Google Scholar
• Van Eijk IC, Peters MJL, Serné EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis. 2009;68(3):362–366. doi:10.1136/ard.2007.086777
   PubMed Web of Science ®Google Scholar
• van Sijl AM, van Eijk IC, Peters MJ, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(1):119–123. doi:10.1136/annrheumdis-2013-203934
   PubMed Web of Science ®Google Scholar
• Zardi EM, Pipita ME, Giorgi C, Lichinchi D, Zardi DM, Afeltra A. Differences in carotid atherosclerosis between patients with ankylosing spondylitis treated with tumor necrosis factor-alpha antagonists and healthy matched controls. Med. 2018;97(27):e11250. doi:10.1097/MD.0000000000011250
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; Ca Rrd study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arter Thromb Vasc Biol. 2011;31(3):705–712. doi:10.1161/ATVBAHA.110.214585
   PubMed Web of Science ®Google Scholar
• Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol. 2018;70(3):408–416. doi:10.1002/art.40366
   PubMed Web of Science ®Google Scholar
• Yang ZS, Lin NN, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016;51(2):240–247. doi:10.1007/s12016-016-8560-9
   PubMed Web of Science ®Google Scholar
• Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019;155(6):700–707. doi:10.1001/jamadermatol.2019.0001
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Kitas GD, Dimitroulas T, et al. Cardiovascular magnetic resonance in rheumatology: current status and recommendations for use. Int J Cardiol. 2016;217:135–148. doi:10.1016/j.ijcard.2016.04.158
   PubMed Web of Science ®Google Scholar
• Mavrogeni S. Assessment of cardiovascular involvement in Connective Tissue Disease: let’s open Pandora’s box. Mediterr J Rheumatol. 2016;27(3):91–93. doi:10.31138/mjr.27.3.91
   Google Scholar
• Seneviratne MG, Grieve SM, Figtree GA, et al. Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study. Lupus. 2016;25(6):573–581. doi:10.1177/0961203315622275
   PubMed Web of Science ®Google Scholar
• Opinc AH, Makowski MA, Lukasik ZM, Makowska JS. Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies? Heart Fail Rev. 2021;26(1):111–125. doi:10.1007/s10741-019-09909-8
   PubMed Web of Science ®Google Scholar
• Galea N, Rosato E, Gigante A, et al. Early myocardial damage and microvascular dysfunction in asymptomatic patients with systemic sclerosis: a cardiovascular magnetic resonance study with cold pressor test. PLoS One. 2020;15(12):e0244282. doi:10.1371/journal.pone.0244282
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Dimitroulas T, Kitas GD. Cardiovascular magnetic resonance in the diagnosis and management of cardiac and vascular involvement in the systemic vasculitides. Curr Opin Rheumatol. 2019;31(1):16–24. doi:10.1097/BOR.0000000000000560
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, Markousis-Mavrogenis G, Koutsogeorgopoulou L, et al. Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naive patients with connective tissue diseases. Int J Cardiol. 2017;236:151–156. doi:10.1016/j.ijcard.2017.01.104
   PubMed Web of Science ®Google Scholar
• Fijolek J, Wiatr E, Gawryluk D, et al. The significance of cardiac magnetic resonance imaging in detection and monitoring of the treatment efficacy of heart involvement in eosinophilic granulomatosis with polyangiitis patients. Sarcoidosis Vasc Diffus Lung Dis. 2016;33(1):51–58.
   PubMed Web of Science ®Google Scholar
• Miszalski-Jamka T, Szczeklik W, Sokolowska B, et al. Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Am Coll Cardiol. 2015;65(1):103–105. doi:10.1016/j.jacc.2014.08.055
   PubMed Web of Science ®Google Scholar
• Wang CR, Tsai YS, Li WT. Lupus myocarditis receiving the rituximab therapy-a monocentric retrospective study. Clin Rheumatol. 2018;37(6):1701–1707. doi:10.1007/s10067-017-3971-4
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Kobayashi H, Giles J, Yokoe I, Nishiwaki A, Takei M. Impact of biological treatment on left ventricular function and morphology in rheumatoid arthritis patients without cardiac symptoms, assessed by cardiac magnetic resonance imaging. Scand J Rheumatol. 2017;46(4):328–329. doi:10.3109/03009742.2016.1173722
   PubMed Web of Science ®Google Scholar
• Ntusi NAB, Francis JM, Sever E, et al. Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol. 2018;270:253–259. doi:10.1016/j.ijcard.2018.06.099
   PubMed Web of Science ®Google Scholar
• Daien CI, Fesler P, Du Cailar G, et al. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):881–887. doi:10.1136/annrheumdis-2012-201489
   PubMed Web of Science ®Google Scholar
• Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol. 2012;39(4):701–706. doi:10.3899/jrheum.110751
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Nakajima Y, Takei M. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol. 2014;41(10):1916–1921. doi:10.3899/jrheum.131540
   PubMed Web of Science ®Google Scholar
• Ahlers MJ, Lowery BD, Farber-Eger E, et al. Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc. 2020;9(10):e014661.
   PubMed Web of Science ®Google Scholar
• Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38(35):2649–2662. doi:10.1093/eurheartj/ehx321
   PubMed Web of Science ®Google Scholar
• Antoniades L, Sfikakis PP, Mavrikakis M. Glucocorticoid effects on myocardial performance in patients with systemic sclerosis. Clin Exp Rheumatol. 2001;19(4):431–437.
   PubMed Web of Science ®Google Scholar
• Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int. 2007;27(4):369–373. doi:10.1007/s00296-006-0215-3
   PubMed Web of Science ®Google Scholar
• Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn’s patients exposed to TNF-alpha antagonists. Rheumatology (Oxford). 2007;46(11):1688–1693. doi:10.1093/rheumatology/kem212
   PubMed Web of Science ®Google Scholar
• Baniaamam M, Paulus WJ, Blanken AB, Nurmohamed MT. The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. Expert Opin Biol Ther. 2018;18(5):585–594. doi:10.1080/14712598.2018.1462794
   PubMed Web of Science ®Google Scholar
• Tomas L, Lazurova I, Pundova L, et al. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol. 2013;32(1):61–66. doi:10.1007/s10067-012-2091-4
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Sfikakis PP, Dimitroulas T, et al. Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. Rheumatol Int. 2018;38(6):949–958. doi:10.1007/s00296-018-4004-6
   PubMed Web of Science ®Google Scholar
• Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293–2299. doi:10.1002/art.21204
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56(9):2905–2912. doi:10.1002/art.22809
   PubMed Web of Science ®Google Scholar
• Gasparyan AY. Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets. Curr Pharm Des. 2012;18(11):1447–1449. doi:10.2174/138161212799504777
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–328. doi:10.1016/S0140-6736(17)32814-3
   PubMed Web of Science ®Google Scholar
• Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020;16(7):361–379. doi:10.1038/s41584-020-0428-y
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week. J Am Coll Cardiol. 2018;72(25):3320–3331. doi:10.1016/j.jacc.2018.06.082
   PubMed Web of Science ®Google Scholar
• Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39(38):3499–3507. doi:10.1093/eurheartj/ehy310
   PubMed Web of Science ®Google Scholar
• van Hout GP, Bosch L, Ellenbroek GH, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2017;38(11):828–836.
   PubMed Web of Science ®Google Scholar
• van der Heijden T, Kritikou E, Venema W, et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report. Arter Thromb Vasc Biol. 2017;37(8):1457–1461. doi:10.1161/ATVBAHA.117.309575
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–410. doi:10.1016/j.jacc.2012.10.027
   PubMed Web of Science ®Google Scholar
• Provan SA, Lillegraven S, Sexton J, et al. Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. Rheumatol. 2020;59(3):505–512.
   PubMed Web of Science ®Google Scholar
• Lacaille D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M. Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis. 2017;76(6):1057–1063. doi:10.1136/annrheumdis-2016-209562
   PubMed Web of Science ®Google Scholar